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The aim of the research work was to study the NO level in
patients with the I and II degree of arterial hypertension
(AH) and metabolic disorders.
The general research group consists of 75 patients: I group
– 20 patients with normal levels of blood pressure (32.5 ±
3.8 years), II group – 27 patients with AH I (34.6 ± 4.6
years), III group – 28 patients with AH II (36.2 ± 3.7
years), with the duration of hypertension from 1 to 10
years.
The NO level was determined by the summary concentra-
tion of stable NO metabolites – nitrates and nitrits
(CMNO) in plasma (Moshage,1995, WPI Nitralyzer-II,
USA). The lipid spectrum, level of glucose on an empty
stomach and tolerance to glucose were studied, anthropo-
metric research was carried out with the definition of mass
index and the degree of obesity. The daily monitoring of
blood pressure was carried out on the TM-2421 AND
monitor. The analysis of the resieved data showed that in
the II group of patients the level of CMNO was 40.3%
lower, and in the III group of patients it was 96.3% lower,
then in the I group patients.
With the increasing of metabolic disorders degree (the
combination of dyslipidemia, obesity and breach toler-
ance to glucose) the level of CMNO decreses and the level
of blood pressure increases, so the metabolic disorders
degree corresponds the more expressed decrease of NO
production and increase of hypertension degree, which
show the pathogenetic community of metabolic disorders
and arterial hypertension. The decrease of NO production
showed the dependence with blood pressure level, which
increases with the duration of arterial hypertention.
So, metabolism of vasoactive substance NO in young
patients with arterial hypertension depends on the degree
and length of arterial hypertension and the degree of met-
abolic disorders.
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